Table 3.
Results of multivariable analyses
| Outcome | OR (95% CI) | P value |
|---|---|---|
| Multivariable analysis and association with response to vasopressina | ||
| Non-medical ICU | 1.70 (1.18–2.46) | 0.005 |
| Lactate at AVP initiation, mmol/L | 0.93 (0.89–0.97) | < 0.001 |
| Multivariable analysis and association with ICU mortality | ||
| Hemodynamic response to AVP | 0.51 (0.35–0.76) | 0.001 |
| Catecholamine dose, mcg/kg/min | 3.14 (1.36–7.28) | 0.008 |
| Lactate at AVP initiation, mmol/L | 1.10 (1.04–1.18) | 0.002 |
| AKI presence | ||
| Rifle versus no AKI | 3.64 (1.77–7.49) | < 0.001 |
| Injury versus no AKI | 5.80 (1.13–29.60) | 0.035 |
| Failure versus no AKI | 2.63 (1.38–5.01) | 0.003 |
| ESRD versus no AKI | 2.37 (1.27–4.43) | 0.007 |
| APACHE III score | 1.01 (1.01–1.02) | < 0.001 |
| SOFA score | 1.16 (1.08–1.25) | < 0.001 |
| Medical ICU | 1.58 (1.02–2.45) | 0.040 |
| Race (Caucasian) | 1.72 (1.14–2.60) | 0.010 |
| Age | 1.01 (1.00–1.03) | 0.036 |
| Hepatic failure | 0.89 (0.48–1.62) | 0.696 |
AKI acute kidney injury, AVP vasopressin, ESRD end-stage renal dysfunction, SOFA sequential organ failure assessment
aVariables entered into the model but without a statistically significant association with vasopressin response include RIFLE-defined AKI category, corticosteroid use, SOFA score, APACHE III score, hepatic failure, race, age, and catecholamine dosage (in mcg/kg/min)